Results 161 to 170 of about 117,172 (212)
Some of the next articles are maybe not open access.
Somatostatin and somatostatin receptors in fish growth
General and Comparative Endocrinology, 2010Multiple forms of somatostatin (SS) and SS receptors (SSTR) are produced widely in the tissues of fish and interact to coordinate numerous physiological processes. Insight into their role in growth regulation emerged from studies of abnormal growth and of whole animals.
Mark A, Sheridan, Alison L, Hagemeister
openaire +2 more sources
Somatostatin, Somatostatin Receptors, and Pancreatic Cancer
World Journal of Surgery, 2005AbstractSomatostatin may play an important role in the regulation of cancer growth including pancreatic cancer by interaction with somatostatin receptors (SSTRs) on the cell surface. Five SSTRs were cloned, and the function of these SSTRs is addressed in this review.
Min, Li +6 more
openaire +2 more sources
Current Molecular Medicine, 2013
The pharmacological effects (i.e., inhibition of endocrine secretion and cell proliferation) mediated by the hormone somatostatin (SRIF) are derived from its universal high-affinity binding to five different G proteincoupled receptors (GPCRs), named sst1-5.
Ruscica M +4 more
openaire +4 more sources
The pharmacological effects (i.e., inhibition of endocrine secretion and cell proliferation) mediated by the hormone somatostatin (SRIF) are derived from its universal high-affinity binding to five different G proteincoupled receptors (GPCRs), named sst1-5.
Ruscica M +4 more
openaire +4 more sources
Cellular and Molecular Neurobiology, 1995
1. Somatostatin (SRIF) exerts diverse physiological actions in the body including regulation of hormone and neurotransmitter release and neuronal firing activity. Analogs of SRIF are used clinically to treat tumors and cancers and to block the hypersecretion of growth hormone in acromegaly. 2.
openaire +2 more sources
1. Somatostatin (SRIF) exerts diverse physiological actions in the body including regulation of hormone and neurotransmitter release and neuronal firing activity. Analogs of SRIF are used clinically to treat tumors and cancers and to block the hypersecretion of growth hormone in acromegaly. 2.
openaire +2 more sources
Digestion, 2000
Somatostatin is a neuropeptide produced by neuroendocrine, inflammatory and immune cells in response to different stimuli. Somatostatin inhibits various cellular functions including secretions, motility and proliferation. Its action is mediated by five specific somatostatin receptors (sst1-sst5) which belong to the G protein-coupled receptor family ...
N, Benali +4 more
openaire +2 more sources
Somatostatin is a neuropeptide produced by neuroendocrine, inflammatory and immune cells in response to different stimuli. Somatostatin inhibits various cellular functions including secretions, motility and proliferation. Its action is mediated by five specific somatostatin receptors (sst1-sst5) which belong to the G protein-coupled receptor family ...
N, Benali +4 more
openaire +2 more sources
Somatostatin and Somatostatin Receptor Physiology
Endocrine, 2003Since the discovery of somatostatin (SST) over three decades ago, its ubiquitous distribution and manifold functions are still being documented. SST is synthesized in the hypothalamus and transported to the anterior pituitary gland where it tonicaly inhibits GH and TSH secretion as well as being responsible for GH pulsatile release.
openaire +2 more sources
Metabolism, 1990
Hippocampal neurons containing somatostatin have been shown to be vulnerable in some experimental models of epilepsy. In this report, we describe our recent findings about the seizure-related changes in somatostatin in brain tissue and cerebrospinal fluid (CSF) in experimental and human epilepsy.
P J, Riekkinen, A, Pitkänen
openaire +2 more sources
Hippocampal neurons containing somatostatin have been shown to be vulnerable in some experimental models of epilepsy. In this report, we describe our recent findings about the seizure-related changes in somatostatin in brain tissue and cerebrospinal fluid (CSF) in experimental and human epilepsy.
P J, Riekkinen, A, Pitkänen
openaire +2 more sources
Trends in Endocrinology and Metabolism, 1985
It is now well established that the biological actions of tetradecapeptide somatostatin (somatostatin-14, S-14) are receptor-mediated. These receptors were first quantified in GH4C pituitary tumor cells using [125I-Tyr1] S-14 as radioligand which was found to exhibit high non-specific binding to membrane receptor preparations from normal tissues.
Y C, Patel, C B, Srikant
openaire +3 more sources
It is now well established that the biological actions of tetradecapeptide somatostatin (somatostatin-14, S-14) are receptor-mediated. These receptors were first quantified in GH4C pituitary tumor cells using [125I-Tyr1] S-14 as radioligand which was found to exhibit high non-specific binding to membrane receptor preparations from normal tissues.
Y C, Patel, C B, Srikant
openaire +3 more sources
Somatostatin analogues: Are they analogues of somatostatin?
Journal of Endocrinological Investigation, 2002Dear Sir, Somatostatin (SRIH) was discovered because of its surprising inhibitory effect on GH secretion (1), and thus appropriately named. Later on, its ubiquitousness and the inhibiting activity on pancreatic hormones and on other types of hormones, rendered its name too restrictive. It was by then too late to change it.
openaire +2 more sources
Lung Cancer, 1993
Lung carcinoma is the most common cause of death in the western world and is increasing particularly among women. Despite significant developments in our understanding of the molecular biology of this disease our ability to treat the various subtypes of lung cancer has been at a relative standstill for the past decade.
K J, O'Byrne, D N, Carney
openaire +2 more sources
Lung carcinoma is the most common cause of death in the western world and is increasing particularly among women. Despite significant developments in our understanding of the molecular biology of this disease our ability to treat the various subtypes of lung cancer has been at a relative standstill for the past decade.
K J, O'Byrne, D N, Carney
openaire +2 more sources